drugset
Drugs / DAROTROPIUM
last change Feb 2009 re-read 9 days ago

DAROTROPIUM

also known as GSK233705 · Bromure de darotropium · Bromuro de darotropio · DAROTROPIUM BROMIDE · Darotropium cation · Darotropium ion · GSK233705B

Small molecule

Developed for
chronic obstructive pulmonary disease
Investigated by
GlaxoSmithKline

Trials 11

today NCT00749411 · Ph 2 NCT00783003 · Ph 1 NCT00964405 · Ph 1 NCT00671216 · Ph 1 NCT00676052 · Ph 2 NCT00500461 · Ph 1 NCT00453479 · Ph 2 NCT00453687 · Ph 1 NCT00422604 · Ph 2 NCT00376714 · Ph 2 NCT00279019 · Ph 1
2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 16 trials
Phase 1 NCT00783003 Nov 2008 → Feb 2009 chronic obstructive pulmonary disease GlaxoSmithKline Completed No outcome recorded
Phase 1 NCT00964405 Sep → Dec 2008 chronic obstructive pulmonary disease GlaxoSmithKline Completed No outcome recorded
Phase 1 NCT00671216 May → Jul 2008 chronic obstructive pulmonary disease GlaxoSmithKline Completed No outcome recorded
Phase 1 NCT00500461 Jun → Jul 2007 chronic obstructive pulmonary disease GlaxoSmithKline Completed No outcome recorded
Phase 1 NCT00453687 Mar → May 2007 chronic obstructive pulmonary disease GlaxoSmithKline Completed No outcome recorded
Phase 1 NCT00279019 Dec 2005 → Jun 2006 chronic obstructive pulmonary disease GlaxoSmithKline Completed No outcome recorded
Phase 25 trials · 1 met primary
Phase 2 NCT00749411 Nov 2008 → Feb 2009 chronic obstructive pulmonary disease GlaxoSmithKline Completed No outcome recorded
Phase 2 NCT00676052 May → Dec 2008 chronic obstructive pulmonary disease GlaxoSmithKline Completed Met primary
Phase 2 NCT00453479 Mar → Oct 2007 chronic obstructive pulmonary disease GlaxoSmithKline Completed No outcome recorded
Phase 2 NCT00422604 Oct 2006 → May 2007 chronic obstructive pulmonary disease GlaxoSmithKline Completed No outcome recorded
Phase 2 NCT00376714 Aug 2006 → Apr 2007 chronic obstructive pulmonary disease GlaxoSmithKline Completed No outcome recorded

Evidence & citations 11 cited values

Every value below carries the sentence it was read from. 12 sources stand behind the page.

FieldValueCited text
Known as DAROTROPIUM ChEMBL registry synonym — accepted as the source's own label CHEMBL2365940 ↗
Known as Bromure de darotropium ChEMBL registry synonym — accepted as the source's own label CHEMBL2365940 ↗
Known as Bromuro de darotropio ChEMBL registry synonym — accepted as the source's own label CHEMBL2365940 ↗
Known as DAROTROPIUM BROMIDE ChEMBL registry synonym — accepted as the source's own label CHEMBL2365940 ↗
Known as Darotropium cation ChEMBL registry synonym — accepted as the source's own label CHEMBL2365940 ↗
Known as Darotropium ion ChEMBL registry synonym — accepted as the source's own label CHEMBL2365940 ↗
Known as GSK233705 ClinicalTrials.gov intervention name — accepted as the source's own label NCT00671216 ↗
9

NCT00453687 ↗

NCT00279019 ↗

NCT00376714 ↗

NCT00676052 ↗

NCT00422604 ↗

NCT00500461 ↗

NCT00964405 ↗

NCT00749411 ↗

NCT00783003 ↗
Known as GSK233705B ClinicalTrials.gov intervention name — accepted as the source's own label NCT00453479 ↗
Action Inhibit “GSK233705 is a high-affinity specific muscarinic receptor (mAChR) antagonist” NCT00279019 ↗
Modality Small molecule — CHEMBL2365940 ↗
Route Oral “GSK233705 will be given orally” NCT00279019 ↗